About 200 reports

Furthermore, its oral administration will provide a more convenient method for patients with NASH.

  • Digestive System Disorder
  • Market Size
  • Allergan plc
  • Genfit SA
  • Gilead Sciences, Inc.

Although some authors have argued that oral administration may Chapter IV ## Page DIGESTIVE REMEDIES PRODUCTION AND DEMAND ##.

  • Digestive System Disorder
  • China
  • Demand
  • Trade
  • AstraZeneca PLC

WEAKNESSES THE ORAL DOSAGE FORM PROVIDES EASE OF ADMINISTRATION.

  • Digestive System Disorder
  • Allergan plc
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Ironwood Pharmaceuticals, Inc.
  • ASTRAZENECA

It is an oral administration drug.

  • Digestive System Disorder
  • Forecast
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • EMRICASAN SWOT ANALYSIS
  • PRODUCT PROFILE - EMRICASAN

IN A PHASE I/ IIA TRIAL, ORAL ADMINISTRATION OF IMM-##E WAS PROVEN TO BE SAFE IN PATIENTS WITH TYPE ## DIABETES, HYPERLIPIDEMIA, AND NASH.

  • Digestive System Disorder
  • United States
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.
  • 3.11 Amitiza (lubiprostone)

Amitiza is available for oral administration.

  • Digestive System Disorder
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Mechanism Of Action R&D Progress
  • PMKS-005 - DRUG PROFILE

It is formulated as enteric coated tablet for oral administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • AstraZeneca PLC
  • PMKS-005 - DRUG PROFILE
  • TEGOPRAZAN - DRUG PROFILE

It is formulated as enteric coated tablet for oral administration.

  • Acrylonitrile
  • Ammonium Nitrate
  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • PBI-4050 - DRUG PROFILE

The oral administration of PBI-## significantly reduced, the histological lesions and scars in the lungs, inflammatory/ profibrotic cytokines (TGF-β##, CTGF, MCP-##, IL-##p## & IL-##), fibrotic markers (collagen ##, iNOS & fibronectin), remodeling marker

  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • ProMetic Life Sciences Inc.

The drug candidate is administered by oral route.

  • Biguanide
  • Digestive System Disorder
  • Therapy
  • United States
  • GlaxoSmithKline plc
  • RQ-00201894 - DRUG PROFILE
  • RQ-00201894 - DRUG PROFILE

It is formulated as film-coated tablets for oral route of administration.

  • Digestive System Disorder
  • Japan
  • World
  • Product Initiative
  • RaQualia Pharma Inc.

The drug candidate is administered by oral route.

  • Biguanide
  • Digestive System Disorder
  • Therapy
  • United States
  • GlaxoSmithKline plc
  • KBP-3571 - DRUG PROFILE
  • DWP-14012 - DRUG PROFILE

It is formulated as enteric coated tablet for oral administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • Pharmaceutical
  • Therapy
  • PMKS-005 - DRUG PROFILE
  • Peptic Ulcers - Drug Profiles

It is formulated as enteric-coated tablets for oral administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • Pharmaceutical
  • Therapy
  • ESOMEPRAZOLE - DRUG PROFILE
  • IYHCR-17 - DRUG PROFILE

It is formulated as enteric-coated tablets for oral administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • Ironwood Pharmaceuticals, Inc.
  • Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile

The PK data from the three parts of the study revealed that aramchol is appropriate for a once daily oral administration with food.

  • Digestive System Disorder
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.
  • Phase III - Trial Details
  • ESOMEPRAZOLE - DRUG PROFILE

It is formulated as enteric coated tablet for oral administration.

  • Acrylonitrile
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • Ironwood Pharmaceuticals, Inc.
  • Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile

The PK data from the three parts of the study revealed that aramchol is appropriate for a once daily oral administration with food.

  • Digestive System Disorder
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.
  • RQ-00201894 - DRUG PROFILE

It is formulated as film-coated tablets for oral route of administration.

  • Digestive System Disorder
  • Japan
  • World
  • Product Initiative
  • RaQualia Pharma Inc.

Food & Drug Administration (FDA) or any other regulatory authority.

  • Digestive System Disorder
  • United States
  • World
  • Product Initiative
  • Gilead Sciences, Inc.

Nimbus presented Phase ## data (Oral PS-##) showing that NDI-## inhibited de novo lipogenesis in a dose-dependent fashion.

  • Digestive System Disorder
  • United States
  • World
  • Product Initiative
  • Gilead Sciences, Inc.

It is formulated as film coated tablets for oral route of administration.

  • Diabetes
  • Digestive System Disorder
  • United States
  • Product Initiative
  • Evoke Pharma, Inc.
  • VB-703 - DRUG PROFILE

Patients will receive one of several doses of VB-## or a placebo orally once daily for four weeks.

  • Digestive System Disorder
  • Hospital
  • Immunotherapy
  • Therapy
  • TaiwanJ Pharmaceuticals Co., Ltd.

Food and Drug Administration.

  • Cardiovascular Drug
  • Digestive System Disorder
  • Liver Cancer
  • Pathology
  • Therapy
  • Clinical Trial profile. 111 Trial Title
  • Clinical Trial profile. 258 Trial Title

Evaluation of Gastric pH Changes after Administration of PPI Evaluation of Gastric pH Changes after Administration of PPI GDCT## UMIN##, R## Gastrointestinal Duodenal Ulcer, Gastric Ulcers, Gastritis, Reflux Esophagitis (Gastroesophageal Reflux Disease), Zollinge

  • Clinical Trial
  • Digestive System Disorder
  • Therapy
  • China
  • World

It is formulated as film coated tablets for oral route of administration.

  • Diabetes
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Evoke Pharma, Inc.

It is a small molecule administered orally as a tablet.

  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • Kamada Ltd.

It is formulated as concentrate for solution, as injection for intravenous administration and hard gelatin capsule for oral administration.

  • Digestive System Disorder
  • In Vitro Diagnostic Reagent
  • Pharmaceutical
  • Therapy
  • Transplantation
  • internalization and improved efficacy and safety

Statistically significant differences in patient symptoms between the active and placebo groups occurred one day following AK## administration.

  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

It is administered orally.

  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • Kamada Ltd.